Wegovy vs Zepbound (2026): 14.9% vs 20.9% Weight Loss, $349 vs $449/mo

Zepbound (tirzepatide) produces 20.9% body weight loss vs Wegovy's (semaglutide) 14.9% at 68 weeks, per the SURMOUNT-1 and STEP-1 trials. Wegovy self-pay via NovoCare: $349/month. Zepbound self-pay via LillyDirect vials: $299-$449/month depending on dose. With commercial insurance + manufacturer savings card, both drop to $25/month (max $1,300/year). Both are FDA-approved for chronic weight management (Wegovy: June 2021, Zepbound: November 2023). Both are eligible for $50/month Medicare Part D coverage via the GLP-1 Bridge program starting July 1, 2026.

Quick answer by priority: Max weight loss → Zepbound (20.9% vs 14.9%). Lower self-pay price → Wegovy ($349 vs $349-$449). Better insurance coverage → Wegovy (broader commercial formulary acceptance). Switching mid-treatment → both work, but Zepbound's dual GIP/GLP-1 mechanism means escalation is different. For compounded alternatives at $99-$199/mo, see cheapest GLP-1 providers. For tirzepatide-specific options, see cheapest tirzepatide online.

Weight Loss Results: What the Trials Show

The most reliable comparison comes from each drug's pivotal clinical trials — STEP 1 for Wegovy and SURMOUNT-1 for Zepbound. These aren't perfectly comparable (different study populations, slightly different durations), but they're the best data available since no large-scale head-to-head obesity trial has been published.

At the highest dose (15 mg), Zepbound produced roughly 21% body weight loss compared to Wegovy's 15%. That's a clinically meaningful difference — for a 250-pound person, it's the difference between losing 37 pounds (Wegovy) and 52 pounds (Zepbound). However, 57% of Zepbound patients at the highest dose achieved 20%+ weight loss, while only 32% of Wegovy patients reached that threshold.

How They Work: Single vs Dual Receptor

Wegovy (semaglutide) is a GLP-1 receptor agonist. It mimics the natural GLP-1 hormone your gut produces after eating, which slows gastric emptying, reduces appetite, and signals fullness to the brain. It's the same active ingredient as Ozempic (approved for diabetes at a lower dose).

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist. It does everything semaglutide does, but also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP affects fat storage, energy expenditure, and appetite through different pathways than GLP-1 alone. This dual mechanism is believed to explain Zepbound's higher average weight loss in trials.

Tirzepatide is the same active ingredient as Mounjaro (approved for Type 2 diabetes). Zepbound is the weight-loss-specific brand approved in November 2023.

Pricing Comparison: April 2026

Pricing depends heavily on whether you have insurance, which manufacturer programs you use, and how you access the medication. Here's the current landscape:

Zepbound has the lower list price and a more aggressive self-pay program through LillyDirect, with vials starting at $299/mo. Wegovy's self-pay through NovoCare is $349/mo. Both offer $25/mo copays with commercial insurance and manufacturer savings cards. Comprehensive telehealth alternatives with both brand and compounded options: Eden Health $249/mo includes quarterly labs and obesity medicine physicians. For lowest-cost compounded routes, Enhance MD $149/mo tirzepatide or Enhance MD $115/mo semaglutide. The real pricing advantage goes to Zepbound for uninsured patients, and to whichever drug your insurance prefers for insured patients.

Available Formulations

Wegovy currently has more delivery options than Zepbound:

• •Wegovy injectable pen: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg — weekly injection with pre-filled auto-injector
• •Oral Wegovy tablet: Approved December 2025 — a semaglutide pill taken daily. Must be taken on an empty stomach with a small amount of water, then wait 30 minutes before eating. Available at starter doses through platforms like Ro
• •Zepbound injectable pen: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg — weekly injection with pre-filled auto-injector
• •Zepbound single-dose vials: Available through LillyDirect at lower prices than pen injectors — requires drawing into a syringe yourself

If you're needle-averse, Wegovy has a clear advantage with its oral tablet option. Zepbound is injection-only as of April 2026. However, Foundayo (orforglipron) — a different GLP-1 pill by Eli Lilly — was approved April 1, 2026 with no fasting requirements, giving needle-averse patients another Lilly option.

Dose Escalation: How You Ramp Up

Both medications start at low doses and gradually increase to reduce GI side effects. Here's how the standard titration works:

Wegovy reaches its maximum dose in about 4-5 months. Zepbound has more flexibility at the top end — your provider can adjust between 10 mg, 12.5 mg, and 15 mg based on your response and tolerability. This flexibility can be useful if you hit a weight loss plateau.

Side Effects: How They Compare

Both medications cause similar GI side effects, primarily during dose escalation. The rates from the Wegovy and Zepbound prescribing information:

Wegovy has notably higher nausea and vomiting rates in clinical trials. Zepbound appears to be better tolerated overall, with lower GI side effect rates across the board. However, trial populations differ and real-world experiences vary. Both medications' side effects tend to improve after the first 4-8 weeks of each dose level. For a dose-by-dose breakdown of what to expect on Zepbound — including SURMOUNT data for each dose tier and management strategies — see our Zepbound side effects guide.

Insurance Coverage

Insurance coverage is one of the most important practical differences. Both face restrictions, but the landscape differs:

• •Commercial insurance: Coverage varies dramatically by plan. Some insurers prefer Wegovy (because of Novo Nordisk's rebate deals), others prefer Zepbound (Lilly's contracts). Check your formulary or ask your provider to run a benefits check for both
• •Medicare: Neither was covered for weight loss under Part D until the GLP-1 Bridge program launching July 2026, which covers both Wegovy and Zepbound at a $50/mo copay for eligible beneficiaries
• •Prior authorization: Required by most insurers for both drugs. Typical requirements: BMI ≥30 (or ≥27 with comorbidity), documented failed diet/exercise attempts, and sometimes step therapy (trying cheaper medications first)
• •Wegovy cardiovascular indication: Wegovy has an additional FDA approval for cardiovascular risk reduction (based on the SELECT trial), which gives it coverage under some plans that exclude weight-loss-only medications

The cardiovascular indication is Wegovy's biggest insurance advantage. If your insurer denies coverage for weight loss, your provider may be able to prescribe Wegovy for cardiovascular risk reduction if you meet the criteria — this pathway isn't available for Zepbound.

Who Should Choose Wegovy

• •Your insurance covers Wegovy but not Zepbound — check your formulary first
• •You want an oral (pill) option and don't want injections
• •You have cardiovascular risk factors — Wegovy's SELECT trial data may help with insurance approval
• •You're already on Ozempic for diabetes and want to switch to the weight-loss dose
• •You prefer a longer track record — Wegovy has been on the market since June 2021

Who Should Choose Zepbound

• •You want the highest average weight loss based on clinical trial data
• •You're paying out-of-pocket — LillyDirect vials at $299/mo are the best self-pay deal
• •You experienced significant nausea on semaglutide — Zepbound's GI side effects are generally milder
• •You want more dose flexibility at the maintenance level (10, 12.5, or 15 mg options)
• •Your insurance covers Zepbound or has it as a preferred formulary option

Our Recommendation

If weight loss results are your top priority and you're paying cash, Zepbound wins on both efficacy data and self-pay pricing. The dual GIP/GLP-1 mechanism produces about 6 percentage points more weight loss at maximum doses, and LillyDirect's vial program is the cheapest brand-name option on the market.

If insurance coverage is your top priority, check your formulary for both drugs and go with whichever is covered. Wegovy's cardiovascular indication gives it an edge for insurance approval in cases where weight-loss-only coverage is denied.

If you hate needles, Wegovy is your only option among these two (oral tablet available). Though you should also consider Foundayo, a daily GLP-1 pill with no fasting requirements.

Either way, both are effective, FDA-approved medications that produce significant weight loss when combined with diet and exercise. The "wrong" choice here is still a good choice — the biggest factor in your results will be consistency and how well you tolerate dose escalation, not which specific drug you choose.

Not sure which provider to use? Check our ranked list of GLP-1 telehealth providers or take the match quiz to get a personalized recommendation. You can also use the cost calculator to estimate what you'd actually pay based on your insurance and medication preference.